An anti-cataract intravitreal implant has completed non-clinical testing, with an Australian phase 1/2 clinical study now underway.

US-based biopharmaceutical firm Nacuity’s new implant contains a small antioxidant molecule, NPI-002, designed to slow cataract progression. The study will enroll 30 patients undergoing vitrectomy and is expected to be completed in September 2022.